top of page

If you are unable to access any of our publications, please email Daniel Wetterskog to obtain a copy.

Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Grist E, et al. Genome Medicine. 2022

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

Orlando F, et al. NAR Cancer. 2022

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Attard G, et al. Lancet. 2022

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Jayaram A, et al. Ann Oncol. 2021


Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.

Conteduca V, et al. JCO Precision Oncology. 2020


Genome-wide plasma DNA methylation features of metastatic prostate cancer.

Wu A, et al. The Journal of Clinical Investigation. 2020

Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.

Jayaram A, et al. JCO Precision Oncology. 2019

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, et al. Ann Oncol. 2017

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, et al. Sci Transl Med. 2015

Tumor clone dynamics in lethal prostate cancer.

Carreira S, et al. Sci Transl Med. 2014

Selected publications

bottom of page